Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bronchiolitis Obliterans: early-phase trial registry
3 of 10 indexed Bronchiolitis Obliterans trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Bronchiolitis Obliterans: 10 US clinical trials tracked, 3 recruiting.
Bronchiolitis Obliterans is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Zambon SpA, running 2 of these trials.
Enrollment posture brief
Registry condition bronchiolitis-obliterans
OPEN 3 | RECR 30% | LATE 2 | EARLY 4 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Bronchiolitis Obliterans lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bronchiolitis Obliterans on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bronchiolitis Obliterans is recruiting below its size-band peers.
3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Bronchiolitis Obliterans research.
Zambon SpA accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Bronchiolitis Obliterans enrolment sits around 169 participants.
Median target enrolment is 169 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.
-
Bronchiolitis Obliterans splits between interventional and observational designs.
6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Children's Hospital Medical Center, Cincinnati
NCT04098445
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Dana-Farber Cancer Institute
NCT05922761
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
M.D. Anderson Cancer Center
NCT04604522
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Zambon SpA
NCT04039347
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Fred Hutchinson Cancer Center
NCT01206309
INSPIRE Continuation Post-Approval Study
TransMedics
NCT03868904
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Zambon SpA
NCT03656926
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Stephanie Lee
NCT01307462
Mesenchymal Stem Cell Therapy for Lung Rejection
Mayo Clinic
NCT02181712
Hp129 Xenon Imaging and BOS in Lung Transplantation
Children's Hospital Medical Center, Cincinnati
NCT03603899
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Bronchiolitis Obliterans records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bronchiolitis Obliterans trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bronchiolitis Obliterans page
10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Bronchiolitis Obliterans trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zambon SpA sponsors the most Bronchiolitis Obliterans trials on record, review their full trial history before evaluating a specific study. See Zambon SpA's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bronchiolitis Obliterans condition card totals 10 registered trials; most-linked intervention Mesenchymal stem cell 1.0; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.